Reunion Neuroscience Company Profile, Contacts & Intelligence

Biotechnology23 employees
4 contacts with email or phone data4 with email data3 with phone data
Employees
23
Company source estimate
Reachable Contacts
4
Visible contacts with email or phone data
Contacts With Email
4
4 of 4 visible contacts

Reunion Neuroscience Overview

Reunion Neuroscience is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions. In August of 2023, Reunion Neuroscience became a private company and in May 2024, the Company completed a Series A financing co-led by MPM BioImpact and Novo Holdings. Reunion is actively investigating the use of its lead product candidate, RE104, in postpartum depression and adjustment disorder, as well as in additional neuropsychiatric indications where there remains a significant unmet need that is not addressed by the current standard of care. The Company’s lead product candidate, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT. Reunion designed RE104 to deliver a short duration psychedelic experience compared to longer duration psychedelics like psilocybin. In a Phase 1 clinical trial, RE104 produced a psychedelic state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours), while demonstrating a similar, favorable safety profile. RE104 is currently being evaluated in the RECONNECT Phase 2 (NCT06342310) clinical trial, a multicenter, randomized, double-blind, active dose-controlled clinical trial in moderate-to-severe postpartum depression (PPD) patients. Reunion plans to initiate the REKINDLE Phase 2 clinical trial, a randomized, double-blind, parallel-group, dose-controlled trial in adjustment disorder (AjD) in cancer and other medical illnesses. The RECONNECT Phase 2 clinical trial (NCT06342310), a multicenter, randomized, double-blind, active dose-controlled clinical trial, is evaluating the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with moderate-to-severe PPD. To learn more about the study and eligibility for enrollment, please visit www.ppdreconnectstudy.com.

Industry
Biotechnology

Reunion Neuroscience Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

4 contacts with contact data
4 with email data and 3 with phone data in the visible sample.

Reunion Neuroscience People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Reunion Neuroscience Workforce Composition

Seniority breakdown across 4 visible profiles.

Executive
2
Director
1
Individual contributor
1

Compare Similar Companies to Reunion Neuroscience

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
MindMed Biotechnology Research 115 View company
Lykos Therapeutics Biotechnology Research 90 View company
Cybin Inc Biotechnology Research 80 View company
atai Life Sciences Biotechnology Research 76 View company
Beckley Psytech Pharmaceutical Manufacturing 66 View company
MPM BioImpact Venture Capital And Private Equity Principals 61 View company
Seaport Therapeutics Biotechnology Research 55 View company
Latus Bio Biotechnology Research 33 View company
Field Trip Health (Now Stella Mental Health) Wellness And Fitness Services 31 View company
Delphia Therapeutics Biotechnology Research 29 View company